Suppr超能文献

胚胎植入前基因筛查的下一步是什么?临床医生的观点。

What next for preimplantation genetic screening? A clinician's perspective.

作者信息

Yakin Kayhan, Urman Bulent

机构信息

VKF American Hospital of Istanbul, Assisted Reproduction Unit, Guzelbahce Sokak No. 20, Nisantasi, Istanbul 34365, Turkey.

出版信息

Hum Reprod. 2008 Aug;23(8):1686-90. doi: 10.1093/humrep/den241. Epub 2008 Jun 24.

Abstract

Preimplantation genetic screening (PGS) is a technique that has been introduced into clinical practice to screen and eliminate aneuploid embryos from transfer with the intention to improve implantation rates and decrease pregnancy wastage. Although practiced widely throughout the world, PGS unfortunately has been adopted without being subjected to rigorous scientific validation. Data from recent randomized trials have shed doubt on the efficacy of the procedure when used in women with advanced age, one of the target populations for PGS. Other purported indications for the application of this complicated technique such as recurrent implantation failure and recurrent spontaneous abortion have not been subjected to randomized controlled trials. For the best interest of patients, we feel it is timely for a debate regarding the efficacy and safety of PGS.

摘要

植入前基因筛查(PGS)是一项已引入临床实践的技术,旨在筛查并排除非整倍体胚胎以进行移植,从而提高着床率并减少妊娠丢失。尽管PGS在全球范围内广泛应用,但不幸的是,它在未经过严格科学验证的情况下就被采用了。近期随机试验的数据对该程序用于高龄女性(PGS的目标人群之一)时的疗效提出了质疑。这项复杂技术应用的其他所谓适应症,如反复植入失败和反复自然流产,尚未经过随机对照试验验证。为了患者的最大利益,我们认为关于PGS疗效和安全性的辩论时机已到。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验